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Biodegradation is considered to be the key process for the elimination of the majority of pharmaceuticals in the environment. During wastewater treatment 
or once they are disposed in the aquatic environment, pharmaceuticals may transformed to new, structurally-related compounds which are called 
transformation products (TPs). Since most of these compounds are unknowns, their identification is essential not only to provide a comprehensive risk 
assessment on micropollutants in the environment, but also to design improved removal technologies for (pseudo)persistent trace contaminants.  
In this study, batch reactors seeded with activated sludge from the WWTP of Athens were set up to assess biotic, abiotic and sorption losses of a SSRI drug, 
citalopram. TPs were identified by reversed-phase liquid chromatography quadrupole-time-of-flight mass spectrometry (RPLC-QToF-MS). Hydrophilic 
interaction liquid chromatography (HILIC) was also used as a complementary, orthogonal, technique for the identified TPs, instead of NMR. A workflow for 
suspect and non-target screening was developed. A suspect list of possible TPs was compiled by literature and in silico prediction tools (EAWAG-BBD Pathway 
Prediction System and Bruker’s Metabolite Predict). Structure elucidation of TPs was based on accurate mass and isotopic pattern measurements and 
interpretation of MS/MS spectra by the observed fragmentation pattern and library-spectrum match.  
In total, thirteen TPs were identified. Four out of them were fully identified and confirmed by reference standards (desmethylcitalopram, citalopram amide, 
citalopram carboxylic acid and 3-oxo-citalopram). A probable structure based on diagnostic evidence and tentative candidates were proposed for the 
additional five and four TPs, respectively. Finally, a transformation pathway based on the identified compounds was presented. 
 Suspect and non-target screening was 
performed for the identification and structure 
elucidation of  TPs. 
 
 HILIC was used complementary to RP 
(identical MS/MS spectra of TPs in RP and 
HILIC). 
 
 13 TPs were identified in total. 
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Compilation of suspect list of TPs:  
EAWAG-BBD Pathway Prediction System 
+ literature + Metabolite Predict (Bruker) 
Screening  all the time interval 
chromatograms in RP & HILIC  
(+ESI/-ESI)           
Evaluation of tentative candidates: 
meet the set criteria, absence in blank & 
time trend 
Confirmation if  possible with 
reference standard                             
(RT & MS/MS spectra) 
CTR 325 
Citalopram 
CTR 311 
Desmethylcitalopram 
CTR 329 
Desmethylcitalopram amide 
CTR 330 
Desmethylcitalopram acid 
CTR 343 
Citalopram amide 
CTR 344 
Citalopram acid 
Acquisition of MS/MS spectra in 
RP & HILIC: Interpretation of the 
fragmentation pathway of TPs 
Fig. 4. MS/MS spectra in RP and HILIC and proposed fragments of CTR 343, 
[M+H]+: C20H24FN2O2. 
Fig. 3. XICs of CTR 343 integrated with incubation time  
in RP and HILIC (Time trend & absence in blank). 
Fig. 1. (a) Degradation chart of CTR (b) Linear time-course  plot of  ln (Ct/C0) of CTR. 
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HILIC 
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C3H8N C7H6F C17H14F C18H15FNO 
C19H21FNO 
C20H22FN2O 
Blank Sorption Biotic Abiotic 
Activated Sludge & 
WW Effluent  
from WWTP of Athens 
(Psitalia) 
Simulation of activated sludge process  
with batch reactors 
Fig. 2. Base Peak Chromatograms of (a) biotic sample (b) blank 
sample  (c) biotic sample after background subtraction. 
Biotic Sample 6 days 
Background 
Subtracted 
Biotic Sample  
Blank Sample 6 days  
CTR 339A 
3-oxo-Citalopram 
CTR 341 
Citalopram-N-oxide 
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Appearance of “hidden” 
peaks 
(unknown TPs 
can now be identified) 
Column: 
 
Acclaim C18 
(Dionex-Thermo 
Scientific) 
 
 
(+) ESI 
MeOH & H2O/MeOH, 90:10, both 
amended with Amm. Form. 5 mM, 0.01% 
Formic Acid 
Column: 
 
ACQUITY BEH 
Amide 
(Waters) 
 
 
CTR 359B 
Amide of Citalopram-N-oxide 
CTR 360 
Acid of Citalopram-N-oxide 
CTR 359A 
Criteria 
Accuracy: 5 mDa 
Isotopic fit: 1000 mSigma 
Intensity: 500 (+)/200 (-) 
Area: 2000 (+)/800 (-) 
 
(-) ESI 
MeOH & H2O/MeOH, 90:10, both 
amended with Amm. Acet. 5 mM 
(+) ESI 
H2O & ACN/H2O, 95:5, both amended 
with Amm. Form. 1 mM, 0.01% 
Formic Acid 
(-) ESI 
H2O & ACN/H2O, 95:5, both amended 
with Amm. Form. 10 mM 
→ Spike 2 mg/L 
 
→ Incubation     
time 6 days 
t1/2 (h) 23.1 
k (h-1) 0.0409 
